Sanofi's Sarclisa Subcutaneous Formulation Achieves Co-Primary Endpoints In IRAKLIA Phase 3 Trial For Multiple Myeloma Treatment
Sanofi's Sarclisa Subcutaneous Formulation Achieves Co-Primary Endpoints In IRAKLIA Phase 3 Trial For Multiple Myeloma Treatment
赛诺菲安万特的Sarclisa皮下制剂在治疗多发性骨髓瘤的IRAKLIA三期试验中达成共同主要终点。
New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma
新的Sarclisa皮下制剂在多发性骨髓瘤的IRAKLIA三期研究中达到了共同主要终点
- Sarclisa SC formulation added to Pd for the treatment of R/R MM met the co-primary endpoints in the IRAKLIA phase 3 study, demonstrating non-inferiority compared to Sarclisa IV
- IRAKLIA is the first global phase 3 study to evaluate the SC administration of a cancer treatment via an OBDS
- OBDS is an alternative delivery method designed to improve the patient experience and currently available SC administration
- 将Sarclisa SC制剂添加到Pd中用于R/R Mm的治疗，在IRAKLIA三期研究中达到了共同主要终点，证明其与Sarclisa IV的非劣性
- IRAKLIA是第一个评估通过OBDS进行癌症治疗的皮下给药的全球三期研究
- OBDS是一种替代给药方法，旨在改善患者体验，当前可使用的皮下给药方式
热门讨论
特斯拉财报在即：股价能否继续攀升？
🎙️讨论： 1. 面对特朗普回归，特斯拉股价能否在2025年继续攀升？ 2. 特斯拉将在1月29日盘后公布财报，你认为会超出市场预期吗？
Moo Earnings
01/24 10:26
TSLA财报预告：通过猜测开盘价来获取奖励！